Inhibition of HIV and FIV by methylene blue and light in vitro (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Inhibition of HIV and FIV by methylene blue and light in vitro (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A2140 1993. Unique Identifier : AIDSLINE ICDB/93693094
Floyd RA; Schneider JE Jr; Zhu YQ; North TW; Schinazi RF; Oklahoma Medical Res. Foundation, Oklahoma City, OK 73104

Abstract: Methylene blue (MB) plus light effectively inactivates the RNA viruses R17 and Q beta. We report here that MB plus light effectively inhibits HIV and the feline immunodeficiency virus (FIV) replication in vitro. MB plus light inhibits HIV replication in human peripheral blood mononuclear cells exhibiting an EC50 value of 0.028 uM, whereas its cytotoxicity, IC50 value, was 6.1 uM. MB was at least two times more effective in light as in dark. The effect of MB plus light could not be accounted for by its action on purified HIV reverse transcriptase. MB plus light was also effective in inhibiting FIV with an EC50 of between 0.11 uM and 0.25 uM and also exhibited an enhancement with light. Based on these results, it is suggested that MB plus light could be effective as an agent for blood treatment.
Keywords: Cells, Cultured Human HIV/DRUG EFFECTS/PHYSIOLOGY/*RADIATION EFFECTS Immunodeficiency Virus, Feline/DRUG EFFECTS/PHYSIOLOGY/*RADIATION EFFECTS Leukocytes, Mononuclear/MICROBIOLOGY *Light Methylene Blue/*PHARMACOLOGY Virus Replication ABSTRACTKWDcells,culturedhumanhiv/drugeffects/physiology/KWDradiationeffectsimmunodeficiencyvirus,feline/drugeffects/physiology/KWDradiationeffectsleukocytes,mononuclear/microbiologyKWDlightmethyleneblue/KWDpharmacologyvirusreplicationabstract
930830
M9380831

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .